Get access

The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making

Authors


  • The views expressed in this article are those of the authors and do not necessarily reflect the official views of the Food and Drug Administration.

Corresponding Author:

Yaning Wang, PhD, Office of Clinical Pharmacology, Office of Translational Sciences, Food and Drug Administration, 10903 New Hampshire Avenue, Bldg #51, Rm 1252, Silver Spring, MD 20903, USA Email: Yaning.Wang@fda.hhs.gov

Abstract

To reduce the bias introduced by confounding risk factors, a case-control comparison was incorporated in the exposure-response (ER) analysis to evaluate the recommended dosing regimen for trastuzumab in a pivotal trial. Results of Kaplan-Meier survival analysis suggest that patients with metastatic gastric cancer (mGC) in the lowest quartile trough concentrations of trastuzumab in cycle 1 (Cmin 1) had shorter overall survival (OS) than did those in other quartiles. The result of the case-matched control comparison suggests that adjusting for these risk factors, patients with the lowest quartile of trastuzumab exposure did not benefit from addition of trastuzumab treatment to chemotherapy. The identified subgroup without survival benefit and the ER relationship support the recommendation on conducting clinical trials to identify a treatment regimen with greater exposure and acceptable safety profiles and to prospectively evaluate whether this treatment regimen will result in survival benefit for the identified subgroup.

Get access to the full text of this article

Ancillary